Primary Refractory Ovarian Cancer: Clinical Trials

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	1	Recruiting 1
Phase 2	1	Recruiting 1

Follow Primary Refractory Ovarian Cancer: new trials by email Literature Review of Primary Refractory Ovarian Cancer trials Research Report on Primary Refractory Ovarian Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer	Phase 1 / Phase 2	Recruiting	Genmab	952	2022-12-07	2026-10-07

Narrower conditions

Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Mesothelioma (1)  ·  Ovarian Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)  ·  Uterine Neoplasms (1)

Broader conditions

Adenoma (1)  ·  Adnexal Diseases (1)  ·  Breast Diseases (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Gonadal Disorders (1)  ·  Lung Diseases (1)

Interventions

Bevacizumab (1)  ·  Carboplatin (1)  ·  Erythromycin (1)  ·  Itraconazole (1)  ·  pembrolizumab (1)

Sponsors

Genmab (1)

Countries

China (1)  ·  Japan (1)  ·  United States (1)